Publications by authors named "Nicholas J Antos"

Background: Genetic modifiers have been identified that increase the risks of lung disease and other complications, such as diabetes in people with cystic fibrosis (CF). Variants in the hemochromatosis gene (HFE) were reported in a study of adults to be associated with worse lung disease.

Objectives: To ascertain the frequency of HFE variants, particularly C282Y (c.

View Article and Find Full Text PDF
Article Synopsis
  • A study on infants with cystic fibrosis (CF) examined the impact of acid blocker therapy (ABT) on growth, gut microbiome (GM), and early lung disease, finding that over half of the participants used ABT by age 3.* -
  • Although ABT use was more prevalent among children with pancreatic insufficiency, it did not lead to significant growth improvements; instead, it was linked to lower GM diversity and more severe lung disease.* -
  • The research highlights the need for careful evaluation of ABT's risks and benefits, suggesting that current treatment guidelines for young children with CF require reevaluation.*
View Article and Find Full Text PDF

Background And Objectives: There are limited data on cystic fibrosis (CF) transmembrane conductance regulator-related metabolic syndrome (CRMS) outcomes beyond infancy. The goal of this study was to analyze outcomes of infants with CRMS up to the age of 9-10 years using the CF Foundation Patient Registry (CFFPR).

Methods: We analyzed data from the CFFPR for individuals with CF and CRMS born between 2010 and 2020.

View Article and Find Full Text PDF

The outlook for those with cystic fibrosis (CF) has never been brighter with ever increasing life expectancy and the approval of the highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor. With that being said, the progressive pulmonary decline and importance of lung health, infection, and inflammation in CF remains. This review is the second part in a three-part CF Year in Review 2020.

View Article and Find Full Text PDF

Guidelines recommend breastfeeding in cystic fibrosis (CF) but breastfeeding rates decline rapidly in CF. We initiated a quality improvement project to improve breastfeeding in CF by incorporating International Board-Certified Lactation Consultants (IBCLC) into the initial CF-diagnosis visit to support mothers who were breastfeeding at diagnosis. In the preintervention group, only 8/14 (57%) continued to provide breast milk after the first visit, whereas postintervention, 16/17 (94%) mothers continued to do so (P = 0.

View Article and Find Full Text PDF

Background: Pulmonary exacerbations (PEx) in cystic fibrosis (CF) are a frequent cause of hospitalisations and lead to long-term decline in pulmonary function. Successful CF inpatient care requires the coordination of multiple providers and complex therapies. Children's Hospital of Wisconsin (CHW) and Children's Healthcare of Atlanta (CHoA) independently identified PEx inpatient care for focused improvements, with emphasis on improving care coordination and patient outcomes.

View Article and Find Full Text PDF